X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6930) 6930
Newspaper Article (555) 555
Newsletter (383) 383
Magazine Article (133) 133
Transcript (38) 38
Book Review (8) 8
Dissertation (3) 3
Government Document (3) 3
Book / eBook (2) 2
Publication (2) 2
Conference Proceeding (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4938) 4938
male (3849) 3849
female (2824) 2824
anticholesteremic agents (2678) 2678
anticholesteremic agents - administration & dosage (2570) 2570
anticholesteremic agents - therapeutic use (2508) 2508
cholesterol (2313) 2313
middle aged (2227) 2227
animals (2020) 2020
anticholesteremic agents - pharmacology (1650) 1650
aged (1596) 1596
cholesterol, ldl - blood (1472) 1472
hypercholesterolemia - drug therapy (1455) 1455
adult (1434) 1434
cholesterol - blood (1319) 1319
hypercholesterolemia (1199) 1199
pharmacology & pharmacy (1164) 1164
statins (1142) 1142
treatment outcome (986) 986
risk factors (984) 984
rats (968) 968
anticholesteremic agents - adverse effects (959) 959
cardiac & cardiovascular systems (928) 928
simvastatin (918) 918
atherosclerosis (890) 890
drug therapy, combination (850) 850
lipids (822) 822
ezetimibe (786) 786
low density lipoproteins (782) 782
atorvastatin (760) 760
triglycerides - blood (755) 755
research (744) 744
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (698) 698
atorvastatin calcium (694) 694
hypercholesterolemia - blood (691) 691
drug therapy (667) 667
dose-response relationship, drug (652) 652
medicine, general & internal (639) 639
double-blind method (625) 625
cholesterol, hdl - blood (609) 609
analysis (592) 592
prevention (575) 575
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (572) 572
dosage and administration (555) 555
lipids - blood (549) 549
mice (542) 542
care and treatment (536) 536
coronary-heart-disease (525) 525
heptanoic acids - administration & dosage (516) 516
pyrroles - administration & dosage (510) 510
health aspects (506) 506
cardiovascular disease (505) 505
pravastatin (502) 502
pharmaceutical industry (499) 499
risk (494) 494
cardiovascular agents (486) 486
time factors (473) 473
cardiovascular diseases - prevention & control (472) 472
nutrition & dietetics (465) 465
simvastatin - administration & dosage (465) 465
diet (439) 439
metabolism (428) 428
peripheral vascular disease (420) 420
cholesterol - metabolism (419) 419
liver - metabolism (416) 416
physiological aspects (413) 413
lipoproteins (408) 408
heptanoic acids - therapeutic use (404) 404
safety (402) 402
pyrroles - therapeutic use (395) 395
efficacy (391) 391
biochemistry & molecular biology (385) 385
cardiovascular diseases (381) 381
therapy (381) 381
diabetes (374) 374
hyperlipidemias - drug therapy (373) 373
cardiovascular (371) 371
abridged index medicus (365) 365
disease (356) 356
azetidines - administration & dosage (355) 355
liver - drug effects (354) 354
triglycerides (348) 348
simvastatin - therapeutic use (342) 342
endocrinology & metabolism (335) 335
anticholesteremic agents - pharmacokinetics (334) 334
antilipemic agents (331) 331
coronary heart disease (330) 330
cardiovascular-disease (328) 328
clinical trials (325) 325
azetidines - therapeutic use (324) 324
density-lipoprotein cholesterol (318) 318
medicine & public health (314) 314
follow-up studies (311) 311
administration, oral (310) 310
aged, 80 and over (309) 309
hyperlipidemia (303) 303
rats, wistar (296) 296
drug interactions (293) 293
blood cholesterol (292) 292
prospective studies (292) 292
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7629) 7629
German (146) 146
Japanese (89) 89
Russian (73) 73
Swedish (55) 55
Spanish (48) 48
Norwegian (41) 41
French (40) 40
Danish (32) 32
Italian (25) 25
Chinese (20) 20
Polish (19) 19
Hungarian (15) 15
Portuguese (13) 13
Czech (10) 10
Dutch (9) 9
Hebrew (2) 2
Lithuanian (2) 2
Turkish (2) 2
Croatian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
Journal Article
Cochrane library, ISSN 1465-1858, 2017, Volume 2017, Issue 3, p. CD009868
Background Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide, yet ASCVD risk factor control and secondary... 
Blood Pressure | Drugs | A.1 Drugs | Anticholesteremic Agents | Aspirin | Cardiovascular Diseases | Heart disease prevention | Costs | A.1.3 Other | Placebo Effect | A. Cardiovascular Disease: Primary Prevention | Insurance medicine | Cause of Death | Cholesterol | Randomized Controlled Trials as Topic | Prevention | Platelet Aggregation Inhibitors | Antihypertensive Agents | Heart & circulation | Medicine General & Introductory Medical Sciences | Drug Combinations | POLYPILL-BASED STRATEGY | Humans | Antihypertensive Agents [administration & dosage] | Anticholesteremic Agents [administration & dosage] | Cardiovascular Diseases [mortality; prevention & control] | RANDOMIZED CONTROLLED-TRIAL | PROACTIVE MULTIFACTORIAL INTERVENTION | Aspirin [administration & dosage] | USUAL CARE | MEDICINE, GENERAL & INTERNAL | Platelet Aggregation Inhibitors [administration & dosage] | HIGH-RISK | DOUBLE-BLIND | SINGLE-PILL COMBINATION | BLOOD-PRESSURE CONTROL | PLACEBO-CONTROLLED TRIAL | CORONARY-HEART-DISEASE | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Anticholesteremic Agents - adverse effects | Antihypertensive Agents - adverse effects | Aspirin - administration & dosage | Aspirin - adverse effects | Anticholesteremic Agents - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Platelet Aggregation Inhibitors - adverse effects
Journal Article
The American journal of medicine, ISSN 0002-9343, 2012, Volume 125, Issue 9, pp. 882 - 887.e1
Abstract Objective Combination therapy, specifically with aspirin, cholesterol and blood pressure-lowering drugs, substantially reduces the risk of coronary... 
Internal Medicine | Adherence | Prevention | Cardiovascular disease | PERSISTENCE | ACUTE CORONARY SYNDROMES | CONVERTING ENZYME-INHIBITORS | SECONDARY PREVENTION | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | STATIN THERAPY | ACUTE MYOCARDIAL-INFARCTION | BETA-BLOCKERS | MEDICATION ADHERENCE | ARTERY-DISEASE | Drug Costs | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Medication Adherence - statistics & numerical data | Cardiovascular Agents - administration & dosage | Age Factors | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Antihypertensive Agents - administration & dosage | Secondary Prevention - methods | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Aspirin - administration & dosage | Drug Prescriptions - statistics & numerical data | Self Administration | Time Factors | Anticholesteremic Agents - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Calcium Channel Blockers - administration & dosage | Primary Prevention - methods | Sodium Chloride Symporter Inhibitors - administration & dosage | Myocardial Infarction - prevention & control | Adrenergic beta-Antagonists - administration & dosage | Angiotensin Receptor Antagonists - administration & dosage | Research | Patient compliance | Coronary heart disease | Drugs | Myocardial infarction | Aspirin | Side effects | Enzyme inhibitors | Risk reduction | Age | Statins
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2012, Volume 59, Issue 25, pp. 2344 - 2353
Objectives The primary objective of this study was to evaluate the low-density lipoprotein cholesterol (LDL-C)–lowering efficacy of 5 SAR236553/REGN727... 
Cardiovascular | Internal Medicine | statin | low-density lipoprotein cholesterol | safety | apolipoprotein-B | PCSK9 | SAR236553/REGN727 | hypercholesterolemia | CUTANEOUS VASCULITIS | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | CHOLESTEROL | CARDIOVASCULAR OUTCOMES | LOW-DENSITY-LIPOPROTEIN | PREVENTION | REDUCTION | DISEASE | 14 RANDOMIZED-TRIALS | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Proprotein Convertases - antagonists & inhibitors | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Time Factors | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - blood | Double-Blind Method | Proprotein Convertases - metabolism | Treatment Outcome | Anticholesteremic Agents - adverse effects | Drug Synergism | Atorvastatin Calcium | Anticholesteremic Agents - therapeutic use | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Aged | Serine Endopeptidases - metabolism | Proprotein Convertase 9 | Care and treatment | Serine | Low density lipoproteins | Antibodies | Thrombin | Lipoprotein A | Cholesterol | Cardiovascular agents | Antilipemic agents | Viral antibodies | Complications and side effects | Hypercholesterolemia | Proteases | Monoclonal antibodies | Universities and colleges | Laboratories | Lipids | Triglycerides | Lipoproteins | Pain | Influenza | Patient safety | Population | Mutation | Clinical medicine | Diabetes | Statins
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 15, pp. 1430 - 1440
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9786, pp. 182 - 197
Summary The increasing prevalence, variable pathogenesis, progressive natural history, and complications of type 2 diabetes emphasise the urgent need for new... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | GLUCAGON-LIKE PEPTIDE-1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | ALPHA-CELL DYSFUNCTION | SMALL-MOLECULE | INSULIN-RESISTANCE | DOUBLE-BLIND | BARIATRIC SURGERY | BETA-CELL | INADEQUATE GLYCEMIC CONTROL | Glucokinase - physiology | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Allylamine - therapeutic use | Liver - physiopathology | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Liver - drug effects | Insulin Resistance - physiology | Allylamine - pharmacology | Receptors, Dopamine D2 - drug effects | Glucagon-Like Peptide 1 - analysis | Venoms - administration & dosage | Indoles - pharmacology | Hyperglycemia - physiopathology | Colesevelam Hydrochloride | Bariatric Surgery | Hypoglycemic Agents - therapeutic use | Insulin-Secreting Cells - physiology | Obesity - surgery | Insulin - pharmacology | Comorbidity | Receptors, Dopamine D2 - agonists | Allylamine - analogs & derivatives | Treatment Outcome | Cardiovascular System - drug effects | 11-beta-Hydroxysteroid Dehydrogenase Type 1 - antagonists & inhibitors | Bile Acids and Salts | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Randomized Controlled Trials as Topic | Anticholesteremic Agents - therapeutic use | Diabetes Mellitus, Type 2 - physiopathology | Insulin-Secreting Cells - drug effects | Signal Transduction - drug effects | Obesity - epidemiology | Indoles - therapeutic use | Signal Transduction - physiology | Diabetes Mellitus, Type 2 - drug therapy | Anticholesteremic Agents - pharmacology | Type 2 diabetes | Technology application | Care and treatment | Therapeutics | Diagnosis | Research | Homeopathy | Materia medica and therapeutics | Obesity | Medical research | Insulin resistance | Diabetes | Insulin
Journal Article
Journal of ethnopharmacology, ISSN 0378-8741, 02/2017, Volume 198, pp. 399 - 406
Vernonia condensata Baker (Asteraceae) is traditionally used in South American Countries as an anti-inflammatory, analgesic and hepatoprotective. This study... 
Vernonia condensate | Hepatoprotective | Antioxidant | 1,5-dicaffeoylquinic acid | Anti-inflammatory | CHEMISTRY, MEDICINAL | RAW 264.7 | FLAVONOIDS | ACUTE TOXICITY | PLANT SCIENCES | NITRIC-OXIDE PRODUCTION | ACETAMINOPHEN | TETRACHLORIDE-INDUCED HEPATOTOXICITY | CHLOROGENIC ACID | INTEGRATIVE & COMPLEMENTARY MEDICINE | KUPFFER CELLS | PHARMACOLOGY & PHARMACY | TNF-ALPHA | EXTRACT | Rats, Wistar | Drug Overdose | Plant Extracts - pharmacology | Plant Leaves | Acetaminophen - administration & dosage | Male | Dose-Response Relationship, Drug | Plant Extracts - administration & dosage | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - isolation & purification | Silymarin - pharmacology | Vernonia - chemistry | Chemical and Drug Induced Liver Injury - etiology | Cell Line | Chemical and Drug Induced Liver Injury - prevention & control | Cytokines - metabolism | Acetaminophen - toxicity | Anti-Inflammatory Agents - pharmacology | Rats | Antioxidants - pharmacology | Anticholesteremic Agents - isolation & purification | Macrophages - metabolism | Animals | Antioxidants - isolation & purification | Anticholesteremic Agents - administration & dosage | Antioxidants - administration & dosage | Macrophages - drug effects | Mice | Anticholesteremic Agents - pharmacology | Antioxidants | Research institutes | Anti-inflammatory drugs | Analysis | Anticholesteremic agents | Medicinal plants | Analysis and chemistry | Low density lipoproteins | Medicine, Botanic | Esters | Medicine, Herbal | Blood
Journal Article
Atherosclerosis, ISSN 0021-9150, 2009, Volume 204, Issue 2, pp. 476 - 482
Abstract Background Risk factors of cardiovascular disease such as lipid aberrations, hypertension, abdominal adiposity and elevations in systemic... 
Cardiovascular | Cardiovascular disease | Inflammation | Hyperlipidemia | Plant sterols | Omega-3 fatty acids | C-REACTIVE PROTEIN | MYOCARDIAL-INFARCTION | SUDDEN-DEATH | OMEGA-3-FATTY-ACIDS | RISK | PHYTOSTEROLS | CARDIOVASCULAR-DISEASE | PERIPHERAL VASCULAR DISEASE | FISH-OIL | CORONARY-HEART-DISEASE | DOCOSAHEXAENOIC ACIDS | Blood Pressure | Body Composition | Hyperlipidemias - blood | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Hypolipidemic Agents - blood | Capsules | Lipids - blood | Anti-Inflammatory Agents - therapeutic use | Cardiovascular Diseases - blood | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Hyperlipidemias - diet therapy | Hyperlipidemias - physiopathology | Phytosterols - therapeutic use | Hyperlipidemias - complications | Fatty Acids, Omega-3 - administration & dosage | Cardiovascular Diseases - etiology | Cardiovascular Diseases - physiopathology | Double-Blind Method | Risk Assessment | Administration, Oral | Risk Factors | Inflammation Mediators - blood | Treatment Outcome | Anti-Inflammatory Agents - blood | Phytosterols - administration & dosage | Phytosterols - blood | Hypolipidemic Agents - administration & dosage | Fatty Acids, Omega-3 - therapeutic use | Fatty Acids, Omega-3 - blood | Aged | Hypolipidemic Agents - therapeutic use | Dietary Supplements | Hypertension | Unsaturated fatty acids | Anti-inflammatory drugs | Analysis | Phytosterols | Anticholesteremic agents | Atherosclerosis
Journal Article